Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
SPRB Stock Summary
Top 10 Correlated ETFs
SPRB
In the News
Spruce Biosciences (SPRB) Upgraded to Buy: Here's What You Should Know
Spruce Biosciences (SPRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Spruce Biosciences (SPRB) Falls 86% in a Month: Here's Why
Spruce Biosciences' (SPRB) CAHmelia-203 phase IIb study of tildacerfont in adult patients with CAH fails to meet the primary efficacy endpoint.
Why Is Spruce Biosciences (SPRB) Stock Down 78% Today?
Spruce Biosciences (NASDAQ: SPRB ) stock is falling hard on Thursday after the biopharmaceutical company posted two new updates for investors. The first big update that has investors in SPRB stock reeling are the results of a Phase 2b clinical trial of tildacerfont in adult patients with classic congenital adrenal hyperplasia ( CAH ).
Spruce Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024 at 2:40 p.m. ET. Interested parties can access the live webcast here.
Top 4 Health Care Stocks That May Rocket Higher This Month - Generation Bio (NASDAQ:GBIO), Evelo Biosciences (NASDAQ:EVLO)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Spruce Biosciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $SPRB--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023, at 3:30 p.m. ET. Interested parties can access the live webcast here.
Best Penny Stocks To Buy? 3 To Watch With Targets Up To 400%
Analysts like these penny stocks but is it time to buy or not? The post Best Penny Stocks To Buy?
Penny Stocks To Buy? 4 Cheap Stocks To Watch Right Now
High volume penny stocks to watch right now. The post Penny Stocks To Buy?
Spruce Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #Tildacerfont--Spruce Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Spruce Biosciences Stock (SPRB): Why The Price Jumped
The stock price of Spruce Biosciences Inc (NASDAQ: SPRB) increased by 13.48% in the most recent trading session. This is why it happened.
SPRB Financial details
SPRB Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0.26 | |
Net income per share | -1.45 | -5.01 | -1.83 | -1.92 | -1.24 | |
Operating cash flow per share | -1.38 | -4.59 | -1.54 | -1.77 | -0.86 | |
Free cash flow per share | -1.38 | -4.61 | -1.54 | -1.77 | -0.86 | |
Cash per share | 0.43 | 26.23 | 3.81 | 3.36 | 2.5 | |
Book value per share | -3.35 | 24.94 | 4.77 | 2.91 | 1.99 | |
Tangible book value per share | -3.35 | 24.94 | 4.77 | 2.91 | 1.99 | |
Share holders equity per share | -3.35 | 24.94 | 4.77 | 2.91 | 1.99 | |
Interest debt per share | 0.49 | 1.08 | 0.29 | 0.28 | 0.11 | |
Market cap | 155.44M | 145.65M | 104.19M | 25.88M | 112.83M | |
Enterprise value | 155.96M | -5.37M | 67.61M | 7.57M | 21.1M | |
P/E ratio | -11.74 | -4.85 | -2.44 | -0.57 | -2.35 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 11.18 | |
POCF ratio | -12.32 | -5.29 | -2.9 | -0.62 | -3.39 | |
PFCF ratio | -12.32 | -5.28 | -2.9 | -0.62 | -3.39 | |
P/B Ratio | -5.07 | 0.97 | 0.94 | 0.38 | 1.47 | |
PTB ratio | -5.07 | 0.97 | 0.94 | 0.38 | 1.47 | |
EV to sales | 0 | 0 | 0 | 0 | 2.09 | |
Enterprise value over EBITDA | -11.99 | 0.18 | -1.61 | -0.17 | -0.41 | |
EV to operating cash flow | -12.36 | 0.2 | -1.88 | -0.18 | -0.63 | |
EV to free cash flow | -12.36 | 0.19 | -1.88 | -0.18 | -0.63 | |
Earnings yield | -0.09 | -0.21 | -0.41 | -1.74 | -0.42 | |
Free cash flow yield | -0.08 | -0.19 | -0.35 | -1.61 | -0.29 | |
Debt to equity | -0.15 | 0.04 | 0.06 | 0.09 | 0.05 | |
Debt to assets | 0.95 | 0.04 | 0.05 | 0.07 | 0.03 | |
Net debt to EBITDA | -0.04 | 5.17 | 0.87 | 0.4 | 1.77 | |
Current ratio | 1.08 | 16.43 | 10.36 | 6.72 | 4.18 | |
Interest coverage | -201.65 | -91.07 | -121.93 | -112.58 | -107.65 | |
Income quality | 0.96 | 0.93 | 0.85 | 0.9 | 0.69 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | -0.01 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 1.25 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 4.9 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.33 | -2.06 | -1.37 | -0.11 | -0.1 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0.46 | |
Graham number | 10.45 | 53.03 | 14 | 11.2 | 7.46 | |
ROIC | 0.51 | -0.19 | -0.36 | -0.61 | -0.64 | |
Return on tangible assets | -2.82 | -0.18 | -0.34 | -0.53 | -0.46 | |
Graham Net | -3.43 | 23.98 | 3.16 | 2.63 | 1.79 | |
Working capital | 349K | 150.63M | 83.02M | 71.16M | 77.72M | |
Tangible asset value | -30.64M | 149.43M | 111.37M | 68.49M | 76.51M | |
Net current asset value | -30.68M | 146.94M | 76.78M | 66.45M | 74.75M | |
Invested capital | -0.15 | 0.04 | 0.06 | 0.09 | 0.05 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 2.09M | 2.75M | 3.23M | 2.12M | 2.38M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 57.12K | 12.98K | 2.7K | 1.21K | 17.37K | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.01 | 0.03 | 0.13 | 0.3 | 0.02 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0.43 | -0.2 | -0.38 | -0.66 | -0.63 | |
Capex per share | 0 | -0.01 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0.06 | 0.05 | 0.08 | 0.07 | |
Net income per share | -0.43 | -0.39 | -0.32 | -0.3 | -0.24 | |
Operating cash flow per share | -0.5 | -0.37 | 0.05 | -0.3 | -0.27 | |
Free cash flow per share | -0.5 | -0.37 | 0.05 | -0.3 | -0.27 | |
Cash per share | 3.36 | 3.72 | 2.97 | 2.65 | 2.35 | |
Book value per share | 2.91 | 3.39 | 2.38 | 2.1 | 1.86 | |
Tangible book value per share | 2.91 | 3.39 | 2.38 | 2.1 | 1.86 | |
Share holders equity per share | 2.91 | 3.39 | 2.38 | 2.1 | 1.86 | |
Interest debt per share | 0.27 | 0.18 | 0.13 | 0.12 | 0.09 | |
Market cap | 25.88M | 70.5M | 87.18M | 92.01M | 120.22M | |
Enterprise value | 7.71M | 2.31M | -5.03M | -1.73M | 28.49M | |
P/E ratio | -0.63 | -1.41 | -1.7 | -1.86 | -3.02 | |
Price to sales ratio | 0 | 35.9 | 40.27 | 29.94 | 41.64 | |
POCF ratio | -2.2 | -5.98 | 43.74 | -7.5 | -10.73 | |
PFCF ratio | -2.2 | -5.98 | 43.74 | -7.49 | -10.73 | |
P/B Ratio | 0.38 | 0.65 | 0.9 | 1.08 | 1.57 | |
PTB ratio | 0.38 | 0.65 | 0.9 | 1.08 | 1.57 | |
EV to sales | 0 | 1.17 | -2.32 | -0.56 | 9.87 | |
Enterprise value over EBITDA | -0.7 | -0.18 | 0.4 | 0.13 | -2.56 | |
EV to operating cash flow | -0.66 | -0.2 | -2.52 | 0.14 | -2.54 | |
EV to free cash flow | -0.66 | -0.2 | -2.52 | 0.14 | -2.54 | |
Earnings yield | -0.39 | -0.18 | -0.15 | -0.13 | -0.08 | |
Free cash flow yield | -0.45 | -0.17 | 0.02 | -0.13 | -0.09 | |
Debt to equity | 0.09 | 0.05 | 0.05 | 0.06 | 0.05 | |
Debt to assets | 0.07 | 0.04 | 0.04 | 0.04 | 0.03 | |
Net debt to EBITDA | 1.65 | 5.39 | 7.26 | 6.86 | 8.23 | |
Current ratio | 6.72 | 5.97 | 5.46 | 4.59 | 4.18 | |
Interest coverage | -93.88 | -100.76 | -110.02 | 114.77 | -105.32 | |
Income quality | 1.05 | 0.92 | -0.16 | 0.99 | 1.13 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 1.76 | 1.39 | 1.05 | 1.02 | |
Research and developement to revenue | 0 | 5.96 | 6.06 | 4.39 | 3.84 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.25 | 0 | 0 | -0.41 | 0 | |
Stock based compensation to revenue | 0 | 0.54 | 0.56 | 0.37 | 0.42 | |
Graham number | 5.33 | 5.47 | 4.12 | 3.78 | 3.19 | |
ROIC | -0.15 | -0.11 | -0.15 | -0.15 | -0.14 | |
Return on tangible assets | -0.12 | -0.09 | -0.1 | -0.11 | -0.1 | |
Graham Net | 2.63 | 3.15 | 2.25 | 1.98 | 1.68 | |
Working capital | 71.16M | 114.24M | 101.4M | 86.95M | 77.72M | |
Tangible asset value | 68.49M | 108M | 96.56M | 85.38M | 76.51M | |
Net current asset value | 66.45M | 106.12M | 94.73M | 83.53M | 74.75M | |
Invested capital | 0.09 | 0.05 | 0.05 | 0.06 | 0.05 | |
Average receivables | 0 | 7.5M | 7.5M | 0 | 0 | |
Average payables | 1.8M | 2.44M | 2.2M | 2.05M | 3.24M | |
Average inventory | 0 | 1.7M | 1.7M | 0 | 0 | |
Days sales outstanding | 0 | 687.37 | 0 | 0 | 0 | |
Days payables outstanding | 994.88 | 4.03K | 1.15K | 16.69K | 18.74K | |
Days of inventory on hand | 0 | 3.97K | 0 | 0 | 0 | |
Receivables turnover | 0 | 0.13 | 0 | 0 | 0 | |
Payables turnover | 0.09 | 0.02 | 0.08 | 0.01 | 0 | |
Inventory turnover | 0 | 0.02 | 0 | 0 | 0 | |
ROE | -0.15 | -0.12 | -0.13 | -0.14 | -0.13 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
SPRB Frequently Asked Questions
What is Spruce Biosciences, Inc. stock symbol ?
Spruce Biosciences, Inc. is a US stock , located in Daly city of Ca and trading under the symbol SPRB
What is Spruce Biosciences, Inc. stock quote today ?
Spruce Biosciences, Inc. stock price is $0.7859 today.
Is Spruce Biosciences, Inc. stock public?
Yes, Spruce Biosciences, Inc. is a publicly traded company.